Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)
Curr Oncol. 2024 Jan 24;31(2):660-671. doi: 10.3390/curroncol31020048.ABSTRACTMultidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcome...
Source: Cancer Control - February 23, 2024 Category: Cancer & Oncology Authors: Pedro Villarejo Campos Susana S ánchez García Mariano Amo-Salas Esther Garc ía Santos Carlos L ópez de la Manzanara Ana Alberca David Padilla-Valverde Francisco Javier Redondo Calvo Jes ús Martín Source Type: research
Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)
Curr Oncol. 2024 Jan 24;31(2):660-671. doi: 10.3390/curroncol31020048.ABSTRACTMultidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcome...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Pedro Villarejo Campos Susana S ánchez García Mariano Amo-Salas Esther Garc ía Santos Carlos L ópez de la Manzanara Ana Alberca David Padilla-Valverde Francisco Javier Redondo Calvo Jes ús Martín Source Type: research
Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)
Curr Oncol. 2024 Jan 24;31(2):660-671. doi: 10.3390/curroncol31020048.ABSTRACTMultidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcome...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Pedro Villarejo Campos Susana S ánchez García Mariano Amo-Salas Esther Garc ía Santos Carlos L ópez de la Manzanara Ana Alberca David Padilla-Valverde Francisco Javier Redondo Calvo Jes ús Martín Source Type: research
